Yang L, Zhang J
Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China.
Zhonghua Yan Ke Za Zhi. 2017 Oct 11;53(10):724-728. doi: 10.3760/cma.j.issn.0412-4081.2017.10.002.
Diabetic macular edema (DME), which is the consequence of the failed blood-retinal barrier, has become a leading cause of blindness in diabetic patients. Vascular endothelial growth factors (VEGF) and a series of inflammatory factors participate in the pathophysiology of DME. Laser photocoagulation was accepted as the first-line therapy before anti-VEGF therapy was proved to be more effective by several clinical trials. Anti-VEGF therapy has been regarded as the standard treatment, but there are still lots of cases resistant to anti-VEGF therapy. Corticosteroid treatment has also been proved effective, especially in refractory DME. This demonstrates that inflammation plays a role in DME as well. Here we discuss the situation of anti-VEGF and anti-inflammation therapies for DME. .
糖尿病性黄斑水肿（DME）是血视网膜屏障功能障碍的结果，已成为糖尿病患者失明的主要原因。血管内皮生长因子（VEGF）和一系列炎症因子参与了DME的病理生理过程。在抗VEGF治疗被多项临床试验证明更有效之前，激光光凝术被视为一线治疗方法。抗VEGF治疗已被视为标准治疗方法，但仍有许多病例对抗VEGF治疗耐药。皮质类固醇治疗也已被证明有效，尤其是在难治性DME中。这表明炎症在DME中也起作用。在此我们讨论DME的抗VEGF和抗炎治疗情况。
